CatalystAlert

Search CatalystAlert

Search for companies, drugs, and catalysts

Search CatalystAlert

Search for companies, drugs, and catalysts

BioSpace
Original article

Sentynl bets up to $475M in licensing deal for Mereo’s rare lung disease asset

PartnershipalvelestatPositive
AI Analysis

Summary

Sentynl has agreed to a licensing deal worth up to $475M with Mereo BioPharma for alvelestat, a rare lung disease asset expected to enter Phase 3 development for AATD-LD in 2027.

Clinical Trial Data

Phase

Phase 3

Importance:7/10
Sentiment:
0.60
licensing dealrare diseasePhase 3 entryAATD-LD

Read the original article

Published by BioSpace on August 12, 2026 11:39 AM

Read Original